SIRT1 and breast cancer: Collectively, our results indicate that MDSC-derived miR-155-5p drives HR + breast cancer progression by suppressing SIRT1, and our engineered TME-responsive polymeric micelle system effectively addresses key pharmacological barriers to synergistic cancer treatment.